Clinical trials: Macular Edema
Macular Edema, Retinal Vein Occlusion
Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®
This study will use retrospective data to evaluate the safety and efficacy of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) in the treatment of macular oedema due to retinal vein occlusion (RVO) in clinical practice.
- Trial name
- NCT02181530
- Testing
- No Intervention
- Where
- Poland
- Volunteers
- 43 people
- Sponsor
- Allergan
Branch Retinal Vein Occlusion
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
The purpose of this study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO).
- Trial name
- NCT00406107
- Testing
- pegaptanib sodium (Macugen)
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Palmetto Retina Center, LLC
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
A phase 2, multicenter, randomized, active-controlled, masked, parallel arm study designed to evaluate the safety and efficacy of a single suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension, given…
- Trial name
- TANZANITE (NCT02303184)
- Testing
- 4 mg CLS-TA, IVT aflibercept
- Where
- 14 sites in United States
- Volunteers
- 46 people
- Sponsor
- Clearside Biomedical, Inc.
Diabetic Macular Edema
Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone
Multicentre randomized controlled trial to evaluate whether 5 monthly fixed dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) is as efficacious as Optical coherence tomography (OCT)-guided PRN dosing…
- Trial name
- OZDRY (NCT01892163)
- Testing
- Ozurdex
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Branch Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
- Trial name
- RAPTOR (NCT03802630)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 102 sites in United States, Austria and 17 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Central Retinal Vein Occlusion
Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Central retinal vein occlusion (CRVO) occurs when the main blood vessel that transports blood away from the retina (the very back portion of the eye) becomes blocked, causing the leakage of fluid into the retina and thereby…
- Trial name
- CENTERA (NCT02800642)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 42 sites in Australia, Canada and 6 more
- Volunteers
- 162 people
- Sponsor
- Bayer
Diabetic Macular Edema
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
Laser photocoagulation and intravitreal anti-vascular growth factor injections are commonly used treatment options for individuals with diabetic macular edema.
- Trial name
- DIME (NCT02471651)
- Testing
- Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- California Retina Consultants
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch…
- Trial name
- WAVE (NCT01710839)
- Testing
- 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Charles C Wykoff, PhD, MD
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Macular Edema, Central Retinal Vein Occlusion
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone…
- Trial name
- NCT01231633
- Testing
- Ozurdex, Avastin
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Long Island Vitreoretinal Consultants
Diabetic Macular Edema
Extension Study of MYL-1701P-3001 for Safety and Efficacy
This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.
- Trial name
- NCT04674800
- Testing
- MYL-1701P, a proposed biosimilar to Eylea
- Where
- 15 sites in India
- Volunteers
- 52 people
- Sponsor
- Mylan Pharmaceuticals Inc
Diabetic Macular Edema, Vitrectomy
Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant in the study eye of vitrectomized subjects with diabetic macular edema. Subjects will be followed for 26 weeks.
- Trial name
- NCT00799227
- Testing
- Dexamethasone
- Where
- 2 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macular Edema
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
- Trial name
- NCT01568021
- Testing
- No Intervention
- Where
- 3 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Allergan
Macular Edema
A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema
This study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (DME).
- Trial name
- NCT02121262
- Testing
- Dexamethasone, Laser Photocoagulation
- Where
- 18 sites in China, Philippines
- Volunteers
- 284 people
- Sponsor
- Allergan
Diabetic Retinopathy
Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
To determine the safety and efficacy of intravitreal Aflibercept (Eylea) injection in patients with diabetic retinopathy in the prevention of macular edema following cataract surgery.
- Trial name
- PROMISE (NCT01988246)
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rishi Singh
Uveitis, Macular Edema
Efalizumab to Treat Uveitis
This study examined the safety and potential efficacy of the monoclonal antibody efalizumab (Raptiva) for treating sight-threatening uveitis (eye inflammation).
- Trial name
- NCT00280826
- Testing
- Efalizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema (DME)
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.
- Trial name
- ILUMINATE (NCT02080091)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Alimera Sciences
Uveitis, Uveitis, Posterior
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of…
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- NCT02952001
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 16 sites in United States, India
- Volunteers
- 33 people
- Sponsor
- Clearside Biomedical, Inc.
Diabetic Macular Edema
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
Performance assessment testing may be a useful tool to evaluate the impact of ranibizumab on day-to-day visual function in patients with Diabetic Macular Edema (DME).
- Trial name
- ERASER (NCT02107131)
- Testing
- Intravitreal ranibizumab 0.3mg
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- California Retina Consultants
Diabetic Macular Edema
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1…
- Trial name
- NCT03889444
- Testing
- Dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Allergan